Hans Loibner

5.6k total citations · 1 hit paper
106 papers, 4.0k citations indexed

About

Hans Loibner is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Hans Loibner has authored 106 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 40 papers in Immunology and 38 papers in Oncology. Recurrent topics in Hans Loibner's work include Immunotherapy and Immune Responses (29 papers), Neuroblastoma Research and Treatments (23 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Hans Loibner is often cited by papers focused on Immunotherapy and Immune Responses (29 papers), Neuroblastoma Research and Treatments (23 papers) and Monoclonal and Polyclonal Antibodies Research (22 papers). Hans Loibner collaborates with scholars based in Austria, Germany and United States. Hans Loibner's co-authors include Manfred Schuster, Josef Penninger, Erich Zbiral, Gavin Y. Oudit, Zamaneh Kassiri, Jiuchang Zhong, Fung L. Chow, Danny Guo, Ratnadeep Basu and Evelyne Janzek and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Hans Loibner

100 papers receiving 3.9k citations

Hit Papers

Increased neutrophil-lymphocyte ratio is a poor prognosti... 2013 2026 2017 2021 2013 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
    2013 413 citations Hans Loibner, Hellmut Samonigg et al. British Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans Loibner Austria 31 1.3k 1.2k 907 677 555 106 4.0k
Cody J. Peer United States 33 1.8k 1.3× 1.5k 1.2× 288 0.3× 626 0.9× 97 0.2× 156 4.0k
Ursula Rauch Germany 40 1.7k 1.3× 292 0.2× 1.6k 1.8× 711 1.1× 188 0.3× 113 5.5k
Manfred Schuster Austria 23 835 0.6× 294 0.2× 945 1.0× 321 0.5× 553 1.0× 35 2.5k
Sumio Kawata Japan 45 1.8k 1.3× 984 0.8× 466 0.5× 492 0.7× 62 0.1× 181 6.1k
Philip S. Schein United States 48 1.5k 1.2× 2.4k 1.9× 294 0.3× 600 0.9× 117 0.2× 179 6.5k
Vijay V. Kakkar United Kingdom 37 1.6k 1.2× 429 0.4× 1.4k 1.6× 650 1.0× 55 0.1× 193 5.5k
Gerald J. Roth United States 35 1.9k 1.4× 718 0.6× 1.9k 2.0× 486 0.7× 50 0.1× 82 8.0k
Lionel D. Lewis United States 36 1.4k 1.1× 1.7k 1.4× 79 0.1× 595 0.9× 148 0.3× 167 4.2k
Kenichi Furihata Japan 30 1.1k 0.8× 662 0.5× 330 0.4× 337 0.5× 111 0.2× 118 3.9k
George L. Dale United States 37 890 0.7× 361 0.3× 697 0.8× 713 1.1× 107 0.2× 113 4.3k

Countries citing papers authored by Hans Loibner

Since Specialization
Citations

This map shows the geographic impact of Hans Loibner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Loibner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Loibner more than expected).

Fields of papers citing papers by Hans Loibner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Loibner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Loibner. The network helps show where Hans Loibner may publish in the future.

Co-authorship network of co-authors of Hans Loibner

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Loibner. A scholar is included among the top collaborators of Hans Loibner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Loibner. Hans Loibner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lode, Holger N., Nikolai Siebert, Dominique Valteau‐Couanet, et al.. (2025). Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial. Clinical Cancer Research. 31(17). 3692–3701.
2.
Lode, Holger N., et al.. (2023). Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. British Journal of Cancer. 129(11). 1780–1786. 12 indexed citations
3.
4.
5.
Morris, Zachary S., Lauryn R. Werner, Peter M. Carlson, et al.. (2018). Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunology Research. 6(7). 825–834. 54 indexed citations
6.
Siebert, Nikolai, Karoline Ehlert, Juliet C. Gray, et al.. (2018). Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers. 10(10). 387–387. 14 indexed citations
7.
Ehlert, Karoline, Nikolai Siebert, Silke Kietz, et al.. (2017). Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs. 10(1). 55–61. 52 indexed citations
8.
Siebert, Nikolai, Diana Seidel, Danilo Wegner, et al.. (2016). Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs. 8(3). 604–616. 44 indexed citations
9.
Hinterleitner, Reinhard, Thomas Gruber, Christa Pfeifhofer‐Obermair, et al.. (2012). Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model. PLoS ONE. 7(9). e44295–e44295. 50 indexed citations
10.
Rey-Parra, G, A W Hall, Farah Eaton, et al.. (2012). Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. Journal of Molecular Medicine. 90(6). 637–647. 90 indexed citations
11.
Treml, Benedikt, Nikolaus Neu, Axel Kleinsasser, et al.. (2010). Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Critical Care Medicine. 38(2). 596–601. 89 indexed citations
12.
Zhong, Jiuchang, Haiyan Jin, Xi Yu, et al.. (2010). Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regulatory Peptides. 166(1-3). 90–97. 90 indexed citations
13.
Oudit, Gavin Y., George C. Liu, Jiuchang Zhong, et al.. (2009). Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy. Diabetes. 59(2). 529–538. 249 indexed citations
14.
Dürauer, Astrid, et al.. (2008). Yeast cell surface display system for determination of humoral response to active immunization with a monoclonal antibody against EpCAM. Journal of Biochemical and Biophysical Methods. 70(6). 1109–1115. 2 indexed citations
15.
Dürauer, Astrid, Hans Loibner, Manfred Schuster, et al.. (2007). Humoral immune response to linear EpCAM-peptides induced by the mimotope cancer vaccine IGN101: Assessment by two independent methods. Cancer Research. 67. 1856–1856. 1 indexed citations
16.
17.
Himmler, Gottfried, et al.. (2004). Immunotherapy of malignant diseases – developments and prospects. Wiener Medizinische Wochenschrift. 154(9-10). 235–241. 1 indexed citations
18.
Schlimok, Günter, Klaus Pantel, Hans Loibner, I. Fackler-Schwalbe, & G. Riethmüller. (1995). Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours. European Journal of Cancer. 31(11). 1799–1803. 61 indexed citations
19.
Stahel, R., H. Lacroix, Sculier Jp, et al.. (1992). Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Annals of Oncology. 3(4). 319–320. 18 indexed citations
20.
Steplewski, Zenon, Magdalena Blaszczyk‐Thurin, Michael D. Lubeck, et al.. (1990). Oligosaccharide Y Specific Monoclonal Antibody and Its Isotype Switch Variants. Hybridoma. 9(2). 201–210. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cody J. Peer Breakdown of academic impact, for papers by Ursula Rauch Breakdown of academic impact, for papers by Manfred Schuster Breakdown of academic impact, for papers by Sumio Kawata Breakdown of academic impact, for papers by Philip S. Schein Breakdown of academic impact, for papers by Vijay V. Kakkar Breakdown of academic impact, for papers by Gerald J. Roth Breakdown of academic impact, for papers by Lionel D. Lewis Breakdown of academic impact, for papers by Kenichi Furihata Breakdown of academic impact, for papers by George L. Dale
Rankless by CCL
2026